Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinoma.
Houlston R., Culliford R., Lawrence S., Mills C., Tippu Z., Chubb D., Cornish A., Browining L., Kinnersley B., Bentham R., Sud A., Pallikonda H., Frangou A., Gruber A., Litchfield K., Wedge D., Larkin J., Turajlic S.
Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer, but a comprehensive description of its genomic landscape is lacking. We report the whole genome sequencing of 778 ccRCC patients enrolled in the 100,000 Genomes Project, providing the most detailed somatic mutational landscape to date. We identify new driver genes, which as well as emphasising the major role of epigenetic regulation in ccRCC highlight additional biological pathways extending opportunities for drug repurposing. Genomic characterisation identified patients with divergent clinical outcome; higher number of structural copy number alterations associated with poorer prognosis, whereas VHL mutations were independently associated with a better prognosis. The twin observations that higher T-cell infiltration is associated with better outcome and that genetically predicted immune evasion is not common supports the rationale for immunotherapy. These findings should inform personalised surveillance and treatment strategies for ccRCC patients.